MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 142.6 USD | -5.89% |
|
-14.43% | +43.36% |
| May. 31 | Health Care Stocks Climb On Drug News -- Health Care Roundup | DJ |
| May. 31 | Equities Mostly Rise as Fed's Preferred Inflation Measure Meets Street Views | MT |
Financials (USD)
| Sales 2024 * | 4.17B | Sales 2025 * | 4.84B | Capitalization | 54.63B |
|---|---|---|---|---|---|
| Net income 2024 * | -2.69B | Net income 2025 * | -1.96B | EV / Sales 2024 * | 11.6 x |
| Net cash position 2024 * | 6.25B | Net cash position 2025 * | 3.94B | EV / Sales 2025 * | 10.5 x |
| P/E ratio 2024 * |
-20.2
x | P/E ratio 2025 * |
-27.8
x | Employees | 5,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | -5.89% | ||
| 1 week | -14.43% | ||
| Current month | +0.01% | ||
| 1 month | +29.24% | ||
| 3 months | +54.56% | ||
| 6 months | +83.49% | ||
| Current year | +43.36% |
1 week
140.23
164.73
1 month
114.06170.47
Current year
84.06170.47
1 year
62.55170.47
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 11-02-28 |
James Mock
DFI | Director of Finance/CFO | 47 | 22-09-05 |
Stephen Hoge
PSD | President | 48 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 18-05-31 |
| Director/Board Member | 74 | 20-06-30 | |
Francois Nader
BRD | Director/Board Member | 67 | 19-12-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 142.6 | -5.90% | 7,180,988 |
| 24-05-30 | 151.5 | +2.41% | 4,667,767 |
| 24-05-29 | 147.9 | -3.45% | 5,505,891 |
| 24-05-28 | 153.2 | -8.05% | 6,636,483 |
| 24-05-24 | 166.6 | +1.59% | 5,052,591 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
142.6
USD
Average target price
139.9
USD
Spread / Average Target
-1.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- MRNA Stock
